A double-blind, randomised, placebo controlled, crossover study to assess return of headache in patients treated with 6mg subcutaneous sumatriptan early or late in a migraine attack; with optional open-label doses to assess pattern of use of sumatriptan over the subsequent 72 hour period

Authors
Category Primary study
Registry of TrialsGSK Study Register
Year 1995
This article has no abstract
Epistemonikos ID: 3a0a5426f49607d04aee463fab0295fbe91563f6
First added on: Dec 09, 2024